Stockscreener 앱 받기
62.17
0.02%
0.14
전일 마감가:
$62.03
열려 있는:
$61.83
하루 거래량:
505.98K
Relative Volume:
0.32
시가총액:
$11.25B
수익:
$2.75B
순이익/손실:
$322.29M
주가수익비율:
37.23
EPS:
1.67
순현금흐름:
$300.88M
1주 성능:
-1.49%
1개월 성능:
+2.95%
6개월 성능:
-6.06%
1년 성능:
-24.75%
1일 변동 폭
$61.56
$62.83
1주일 범위
$60.92
$65.40
52주 변동 폭
$52.93
$94.85
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
62.16 | 11.25B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.95 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.22 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.28 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.91 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - Insider Monkey
Biomarin Pharmaceutical (BMRN) Price Target Lowered by Citigroup - GuruFocus
BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Cantor maintains BioMarin stock overweight with $90 target By Investing.com - Investing.com South Africa
BioMarin's First-Quarter Earnings & Sales Beat Estimates - TradingView
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
Cantor maintains BioMarin stock overweight with $90 target - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
BioMarin’s Strong Q1 2025 Performance and Growth Outlook - TipRanks
BioMarin Pharmaceutical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioMarin (BMRN) Reports Strong Q1 2025 Growth and Strategic Adva - GuruFocus
Biomarin Pharma earnings beat by $0.43, revenue topped estimates - Investing.com India
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Earnings call transcript: BioMarin beats Q1 2025 forecasts, stock rises after hours - Investing.com
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets - Yahoo Finance
BMRN Q1 Revenue Surpasses Expectations with Strong Product Deman - GuruFocus
BioMarin: Q1 Earnings Snapshot - News-Times
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Rise - marketscreener.com
BioMarin Pharmaceutical Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) - Seeking Alpha
Biomarin Pharmaceutical Inc. Q1 Profit Increases, Beats Estimates - Nasdaq
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PR Newswire
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin Pharmaceutical Inc expected to post earnings of 71 cents a shareEarnings Preview - TradingView
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings - Barchart.com
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment? - simplywall.st
20 Takeover Rumors Hedge Funds Are Buying - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo
Implied Volatility Surging for BioMarin Stock Options - Yahoo Finance
Oppenheimer maintains BioMarin stock Outperform with $98 target By Investing.com - Investing.com Nigeria
Oppenheimer maintains BioMarin stock Outperform with $98 target - Investing.com
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - Longview News-Journal
BioMarin Earnings Preview: New CEO Alexander Hardy to Reveal First Quarter Strategy Shift - Stock Titan
Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction - Benzinga
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com
Quality Management Process LeadSan RafaelBioMarin Pharmaceutical - Ladders
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? - Yahoo Finance
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day - TradingView
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - Yahoo Finance
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - Yahoo Finance
What Makes BioMarin (BMRN) a New Buy Stock - Yahoo Finance
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오마린 주식 (BMRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Burkhart Erin | GVP, Chief Accounting Officer |
Mar 19 '25 |
Sale |
71.52 |
1,295 |
92,618 |
16,955 |
0.27%
0.30%
자본화:
|
볼륨(24시간):